Objectives: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. Methods: Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (study arm) or continue current ART (continuation arm). Results: In June 2015, 115 patients were evaluable for the primary outcome (56 study, 59 continuation arm). The study was discontinued due to excess of VF in the study arm (7 cases, 12.5%, vs 0 in the continuation arm, p = 0.005). The proportion free of treatment failure was 73.2% in the study and 59.3% in the continuation arm. Two participants in the study and 10 in the continuation arm discontinued therapy due to adverse events (p = 0.030). At VF, no emergent drug resistance was detected. Co-receptor tropism switched to non-R5 in one patient. Patients with VF reported lower adherence and had lower plasma drug levels. Femoral bone mineral density was significantly improved in the study arm. Conclusion: Switching to maraviroc with darunavir/ritonavir qd in virologically suppressed patients was associated with improved tolerability but was virologically inferior to 3-drug therapy.

Rossetti, B., Gagliardini, R., Meini, G., Sterrantino, G., Colangeli, V., Re, M. C., Latini, A., Colafigli, M., Vignale, F., Rusconi, S., Micheli, V., Biagio, A. D., Orofino, G., Ghisetti, V., Fantauzzi, A., Vullo, V., Grima, P., Francisci, D., Mastroianni, C., Antinori, A., Trezzi, M., Lisi, L., Navarra, P., Canovari, B., D’arminio Monforte, A., Lamonica, S., D’avino, A., Zazzi, M., Di Giambenedetto, S., De Luca, A., Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial, <<PLOS ONE>>, N/A; 12 (11): e0187393-N/A. [doi:10.1371/journal.pone.0187393] [http://hdl.handle.net/10807/112984]

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

Rossetti, Barbara;Gagliardini, Roberta;Colafigli, Manuela;Grima, Pierfrancesco;Lisi, Lucia;Navarra, Pierluigi;Lamonica, Silvia;D’Avino, Alessandro;Di Giambenedetto, Simona;De Luca, Andrea
2017

Abstract

Objectives: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. Methods: Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (study arm) or continue current ART (continuation arm). Results: In June 2015, 115 patients were evaluable for the primary outcome (56 study, 59 continuation arm). The study was discontinued due to excess of VF in the study arm (7 cases, 12.5%, vs 0 in the continuation arm, p = 0.005). The proportion free of treatment failure was 73.2% in the study and 59.3% in the continuation arm. Two participants in the study and 10 in the continuation arm discontinued therapy due to adverse events (p = 0.030). At VF, no emergent drug resistance was detected. Co-receptor tropism switched to non-R5 in one patient. Patients with VF reported lower adherence and had lower plasma drug levels. Femoral bone mineral density was significantly improved in the study arm. Conclusion: Switching to maraviroc with darunavir/ritonavir qd in virologically suppressed patients was associated with improved tolerability but was virologically inferior to 3-drug therapy.
Inglese
Rossetti, B., Gagliardini, R., Meini, G., Sterrantino, G., Colangeli, V., Re, M. C., Latini, A., Colafigli, M., Vignale, F., Rusconi, S., Micheli, V., Biagio, A. D., Orofino, G., Ghisetti, V., Fantauzzi, A., Vullo, V., Grima, P., Francisci, D., Mastroianni, C., Antinori, A., Trezzi, M., Lisi, L., Navarra, P., Canovari, B., D’arminio Monforte, A., Lamonica, S., D’avino, A., Zazzi, M., Di Giambenedetto, S., De Luca, A., Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial, <<PLOS ONE>>, N/A; 12 (11): e0187393-N/A. [doi:10.1371/journal.pone.0187393] [http://hdl.handle.net/10807/112984]
File in questo prodotto:
File Dimensione Formato  
Plos one GUSTA 2017.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 2.13 MB
Formato Adobe PDF
2.13 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/112984
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact